Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address the Paradox of Choice

Download All
Hear from experts how the latest data from ASCO 2021 inform therapeutic strategies for patients with R/R MM and how to evaluate novel combination therapeutic regimens. Review their insights in clinical commentaries, slides, a podcast, and an on-demand webcast from a live CCO webinar.
Paul G. Richardson, MD
Program Director
person default
Nina Shah, MD
Peter M. Voorhees, MD

ClinicalThought

The treatment landscape for multiple myeloma is rapidly evolving. Read how expert faculty choose and sequence therapy for patients with relapsed/refractory multiple myeloma to improve patient outcomes.

Paul G. Richardson, MD
Program Director
person default Nina Shah, MD Peter M. Voorhees, MD
Released: August 19, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm
Oncopeptides
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue